Compare Virgin Galactic Holdings, Inc. (SPCE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.89 (market cap $445.69M), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 286.2× Virgin Galactic Holdings, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SPCE | VRTX | |
|---|---|---|
Market Cap | $445.69M | $127.55B |
Volume | 5,128,850 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $7.52 | $557.96 |
52-Week Low | $2.17 | $407.37 |
Typical Hold Time | 69 Days | 120 Days |
Enterprise Value | $409.68M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting ongoing investor skepticism despite recent earnings beats. The company continues to burn cash with negative operating cash flow of $240.14 million in 2025 and deeply negative profit margins. Technical indicators show a bearish trend with the stock trading near key support levels. Recent news highlights management's guidance for positive cash flow by 2027 but also a delay in commercial Delta flights to February 2027.
The outlook remains highly speculative with significant execution risk. While strong ticket demand provides a potential catalyst, the path to profitability is long and dependent on successful commercial spaceflight operations. Investors face substantial dilution risk and high volatility in this pre-revenue growth phase. The stock represents a high-risk, high-reward opportunity suitable only for risk-tolerant investors.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
